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Introduction. Transplantation of pancreas allografts from donors that have experienced preprocurement cardiopulmonary ar-
rest (PPCA) is not common, though use of PPCA grafts is routine in liver and kidney transplantation. This article reviews a large
number of PPCA pancreas grafts at a single center and reports posttransplant outcomes including early graft dysfunction, length
of hospital stay, rejection, and early and late graft survival.Methods. Preprocurement cardiopulmonary arrest, arrest time, and
donor and recipient pancreatic enzyme levels were collected from electronic and written medical records. The PPCA donors were
stratified into 4 groups: none, less than 20 minutes, 20-39 minutes, and 40 minutes or greater. Graft survival was assessed at
7 and 90 days and at 1 year. Long-termgraft survival was assessedbyCox regression analysis.Results.The records of 606 pan-
creas transplants were reviewed, including 328 (54%) simultaneous pancreas and kidney transplants. Preprocurement cardiopul-
monary arrest occurred in 176 donors (29%; median time, 20 minutes). Median peak donor lipase was higher in PPCA donors
(40 μ/L vs 29 μ/L, P = 0.02). Posttransplant, peak recipient amylase, and lipase levels were similar (P = 0.63). Prolonged arrest
time (>40 minutes) was associated with higher donor peak lipase and lower recipient peak amylase (P = 0.05 for both). Stratified
by donor arrest time, there was no difference in 7-day, 90-day, or 1-year graft survival. Cox regression comparing the 4 groups
demonstrated no statistical difference in 10-year survival.Conclusions. These results support transplantation of pancreas allo-
grafts fromPPCAdonors. Prolonged asystole was associatedwith higher peak donor serum lipase but lower peak recipient serum
amylase. There were no differences in allograft survival.
(Transplantation Direct 2018;4: e381; doi: 10.1097/TXD.0000000000000813. Published online 21 August, 2018.)Donor selection for pancreas transplantation is moreconservative as compared with other forms of solid or-
gan transplantation.1 Preprocurement cardiac arrest (PPCA)Received 22 May 2018.
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Transplantation DIRECT ■ 2018time has previously been considered a high-risk donor char-
acteristic and potentially detrimental to overall donor quality
in pancreas transplantation.2 With decreasing numbers of
pancreas transplants performed, reassessment of reasonable
acceptance criteria is a suitable way to expand the donor
pool.3,4 Donor PPCA time is one of several extended donor
criteria that warrants specific evaluation when appraising
the quality of a potential pancreas allograft donor. This is
particularly relevant because recent reports on liver and in-
testine transplantation support the use of organs from do-
nors with PPCAwhen carefully selected for other factors.5-8
In fact, for liver transplantation, a preprocurement arrest
event has actually been hypothesized to potentially provide
protection to the organ from later ischemia and reperfusion
injury.6 This mechanism has been referred to as “ischemic
preconditioning” and is not yet fully understood.9
There have been conflicting reports as to whether PPCA is
a predictor of poor outcome after pancreas transplantation.
It is one of the components that make up the preprocurement
pancreas allocation suitability score which consists exclu-
sively of donor factors (age, body mass index [BMI], inten-
sive care unit stay, asystole, sodium, amylase, lipase, and
inotropic therapy) and is primarily intended to identify suit-
able pancreas donors. In this context, PPCA was identified
as a donor characteristic that was associatedwith a decreased
likelihood of acceptance of the pancreas for transplantation.2www.transplantationdirect.com 1
2 Transplantation DIRECT ■ 2018 www.transplantationdirect.comAlternatively, the Pancreas Donor Risk Index was designed
to help predict graft survival after pancreas transplantation
using data from theOrgan Procurement and Transplantation
Network. This model consists of 8 donor factors (age, sex,
race, height, BMI, serum creatinine, cause of death, and de-
ceased after circulatory death donors) and 2 transplant fac-
tors (cold ischemia time and type of transplant).10 This
index notably does not include PPCA. There have not been
any focused investigations of the individual impact of PPCA
on clinical outcomes and long-term graft survival after pan-
creas transplantation. Additionally, prior studies that have
addressed it as a variable among others have not assessed
specific outcomes associated with varying lengths of arrest
times. This single-center retrospective study was undertaken
to determine if PPCA has an impact on outcome after pan-
creas transplantation.
MATERIALS AND METHODS
This was a retrospective study of all pancreas transplants
performed at a single center from 2003 to 2016. Donor char-
acteristics were obtained from records maintained by the local
organ procurement organization, Indiana Donor Network.
Recipient outcomes, laboratory values, and survival data were
collected from the comprehensive transplant recipient registry
maintained at our center, as well as individual written and
electronic medical records. Recipient inclusion criteria in-
cluded all pancreas transplant recipients, including simulta-
neous pancreas and kidney (SPK), pancreas after kidney
(PAK), or pancreas transplant alone. Recipients receiving a
pancreas allograft as part of a multivisceral or modified
multivisceral transplant were excluded.
All transplant recipients were listed for transplantation in
accordance with standard procedure and protocol as estab-
lished by our center and the United Network for Organ Shar-
ing. In patients that were retransplanted within 30 days of
their initial transplant, data from only the first transplant
were included in this study. Clinical outcomes included
length of stay (LOS) at the hospital and incidence of acute cel-
lular rejection within the first year. Early posttransplant pan-
creas graft function was determined by peak serum amylase
and lipase levels. Early graft survival rates were measured
both by 7-day and 90-day graft loss. Long-term allograft sur-
vival was assessed using Cox regression analysis.
Pancreas allografts were typically procured using an en
bloc technique after aortic flush with preservation solution
and topical cooling with saline slush as previously de-
scribed.11,12 Note that the pancreas had to be accepted for
transplant and appear transplantable by both the procuring
surgeon and the transplanting surgeon to qualify for this
study. Although graft quality is subjective, it is widely ac-
cepted that a normal pancreas would be one with no swell-
ing, no edema, no firmness, no excessive fat, and no injury.
The parenchyma appears normal. The back-table prepara-
tion of the pancreas allograft and transplantation techniques
for each transplant type have also been previously de-
scribed.13-16 Briefly, the recipient operation was performed
through a midline incision. The pancreas was routinely
positioned with the tail toward the pelvis and the head
and duodenum oriented superiorly to facilitate the enteric
anastomosis. Systemic venous drainage was performed to
the vena cava or to the right common iliac vein. Arterial per-
fusion of the allograft was routinely established from theright common iliac artery, although on rare occasions where
this vessel was found to be diseased or had been the site for
arterial anastomosis for a prior transplant, the inflow would
be established either from the aorta or the left common iliac
artery. All pancreas allografts were drained enterically using
a stapled technique as described elsewhere.17 The immuno-
suppression protocol included rabbit antithymocyte globulin
inductionwith early steroidwithdrawal, andmaintenance ther-
apy with tacrolimus and sirolimus or mycophenolate mofe-
til.18,19 All recipients received routine perioperative antibiotics,
prophylaxis against cytomegalovirus with oral valgancyclovir
and prophylaxis against Pneumocystis jiroveci pneumonia with
trimethoprim and sulfamethoxazole, unless contraindicated.
Systemic anticoagulation was not routinely used unless the pa-
tient had a specific history of a coagulation disorder.
The key variable in this study, donor PPCA, was extracted
from the documentation of emergency medical service pro-
viders, as well as emergency department or inpatient hospital
records. The reported donor PPCA times in this study consist
of all reported arrest time before organ procurement. These
events could have occurred outside of the hospital before ar-
rival to the emergency department, or subsequent to inpatient
admission. Preprocurement cardiopulmonary arrest occur-
ring before or after declaration of death was included. All
eventual donors suffering a preprocurement arrest event were
successfully resuscitated and stabilized prior to organ pro-
curement. In the case that exact donor arrest time was un-
known, the time from which cardiopulmonary resuscitation
was initiated until return of spontaneous circulationwas used
as the best estimate of donor PPCA time. The expertise of
those providing resuscitation efforts and quality of cardiopul-
monary resuscitation performed were not available for con-
sideration in this study. The peak donor serum amylase and
lipase levels were obtained from the donor records as well.
Donors were assigned to subgroups stratified by donor PPCA
time (none, less than 20 minutes, 20 to 39 minutes, and
40 minutes or greater).
Standard statistical testing was utilized for continuous and
categorical variables, as indicated. The Cox proportional
hazards model was constructed using a direct entry method.
Covariates were included in the final model for P value less
than 0.10. Statistical testing was performed on SPSS software
(IBM SPSS Statistics Version 24, IBMCorporation, Armonk,
NY). Retrospective analysis of data for pancreas transplant
patients at our centers was reviewed and approved by the in-
stitutional review board of the Indiana University School of
Medicine (1011003619).RESULTS
A total of 606 pancreas transplants (SPK, 54%; PAK,
19%; pancreas transplant alone, 27%) were included in this
study (Table 1). Of these, 176 (29%) donors were recorded
to have had a PPCA event. The median length of arrest time
for these donors was 20 minutes (mean, 23; range, 1 to 90;
standard deviation, 16 minutes). Of the 176 donors that
had experienced an arrest event, 79 (45%) experienced
PPCA time of less than 20 minutes, 75 (43%) between
20 and 39 minutes, and 22 (12%) had an arrest time of
40 minutes or more in duration. Demographics for the entire
group are presented in Table 1. Donor cause of death was the
most significant difference between the donor subgroups, in
TABLE 1.
Demographic data for 606 pancreas transplant patients with comparison of patients in which the deceased donor did or did not
experience cardiopulmonary arrest in the period before organ donation
No donor Any donor Donor cardiopulmonary arrest time
Overall Cardiopulmonary arrest Cardiopulmonary arrest P < 20 min 20 to 40 min > 40 min P*
Overall 606 430 (71%) 176 (29%) 79 (13%) 75 (12%) 22 (4%)
Recipient
Sex: male 56% 57% 55% 0.75 49% 64% 46% 0.22
Race: white 91% 91% 94% 0.36 92% 95% 96% 0.37
Age (median), y 43 43 44 0.45 42 46 44 0.10
BMI (median) 24.9 24.7 25.5 0.13 25.5 24.6 27.5 0.01
Donor
Sex: male 63% 65% 57% 0.06 59% 55% 55% 0.27
Race: white 79% 78% 80% 0.84 80% 80% 82% 0.81
Age (median), y 24 25 22 0.01 21 22 26 0.05
BMI (median) 23.9 23.7 24.8 0.20 24.5 24.9 25.1 0.43
Donor cause of death
Stroke 18% 20% 10% <0.001 9% 9% 14% <0.001
Trauma 60% 72% 31% 43% 22% 19%
Anoxia/other 22% 8% 59% 47% 69% 67%
Donation after cardiac death 2% 1% 3% 0.03 4% 3% 5% 0.16
Regional origin of graft
Local 65% 67% 58% 0.59 60% 61% 50% 0.47
Transplant data
Transplant type 0.87
Pancreas and kidney (n = 328) 54% 55% 53% 0.72 54% 55% 41%
PAK (n = 116) 19% 20% 18% 17% 17% 27%
Pancreas alone (n = 162) 27% 26% 29% 29% 28% 32%
Total ischemia (median), h 8.0 8.4 7.5 0.08 7.3 7.4 8.4 0.29
a Calculated P value for donor cardiopulmonary arrest groups compared with the “no donor cardiopulmonary arrest” group.
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much more likely to have died from anoxic brain injury, as
opposed to trauma or stroke (P = 0.001). A lower-median
age was noted for PPCA donors when compared with the
non-PPCA donor subgroup (P = 0.01). However, the donor
subgroup exceeding 40minutes of PPCA time had the highest
median age (P = 0.05). Recipients were statistically different
only in terms of BMI, in which those receiving an organ from
a donor with PPCA time of greater than 40 minutes had the
highest median BMI (P = 0.01). There were no significant dif-
ferences in regional origin of the graft, or in total ischemia
times. The type of transplant was not significantly different
among any of the donor subgroups.
The median peak preprocurement amylase and lipase
levels for all 176 donors with PPCAwere 84 and 40 μ/L re-
spectively, compared with 77 and 29 μ/L for the 430 donors
with no PPCA (P = 0.42 and P = 0.02) (Table 2). Specifically
looking at the smaller subgroups of donors with PPCA, the
donor group exceeding 40 minutes of PPCA time had the
highest median peak amylase levels compared with all donor
groups (P = 0.78). Median peak lipase levels in the donor
subgroups rose in a corresponding relationship with increas-
ing length of PPCA time (P = 0.05). Posttransplant, the peak
amylase and lipase levels for grafts with donor PPCA time
was 180 and 142 μ/L, respectively, compared with 206 and
157 μ/L for grafts without donor PPCA time (P = 0.63,
P = 0.14). Again, specifically reviewing the subgroups of
PPCA donors, the recipient median peak amylase level wasthe lowest among the donor subgroup exceeding 40 minutes
of PPCA time (P = 0.05).
There was no significant difference in hospital LOS among
any of the PPCA or non-PPCA groups. Acute cellular rejec-
tion within the first year was higher for non-PPCA donors
(5% vs 2%, P = 0.06). A trend of increasing rejection was
seen increasing PPCA time, but this did not reach statistical
significance (0%, 3%, 5%; P = 0.18). Assessing graft survival
by length of donor arrest time, there was no difference in
graft loss at 7 or 90 days posttransplant for any PPCA time
or for increasing PPCA time. Additionally, there was no dif-
ference in 1-year pancreas (or kidney for SPK recipients) allo-
graft or patient survival, with all groups maintaining survival
rates greater than 90% at 1 year.
Cox regression analysis was used to compare 10-year graft
survival between non-PPCA and PPCA subgroups (Figure 1A),
and no difference was noted (P = 0.50). The same analysis was
performed for PPCA grafts only, and there was a clear
disadvantage for the grafts with 40 minutes or more of
PPCA time, but this did not reach significance (Figure 1B).
Finally, assessing kidney grafts in SPK transplants, there
was no difference in graft survival at 10 years. (Figure 1C).DISCUSSION
This single-center study provides the first focused analysis
of the impact of donor PPCA time on pancreas transplanta-
tion outcomes. Similar to other research of this type
TABLE 2.
Comparison of graft laboratory values and posttransplant outcomes by donor arrest time
No donor Any donor Donor cardiopulmonary arrest time
Overall Cardiopulmonary arrest Cardiopulmonary arrest P < 20 min 20 to 40 min > 40 min Pa
Overall 606 430 (71%) 176 (29%) 79 (13%) 75 (12%) 22 (4%)
Donor laboratory value (median)
Peak amylase 78 77 84 0.42 77 79 163 0.78
Peak lipase 31 29 40 0.02 37 41 76 0.05
Recipient laboratory values (median)
Peak amylase 202 206 180 0.63 276 164 105 0.05
Peak lipase 154 157 142 0.14 159 86 187 0.53
Hospital LOS (days, median) 7 7 7 0.38 8 7 6 0.26
Acute cellular rejection first year 25 (4.1%) 22 (5.1%) 3 (1.7%) 0.06 0 (0%) 2 (2.7%) 1 (4.5%) 0.18
Survival
7-d Pancreas graft loss 20 (3.3%) 12 (2.8%) 8 (4.5%) 0.27 4 (5.1%) 3 (4.0%) 1 (4.5%) 0.72
90-d Pancreas graft loss 33 (5.4%) 24 (5.6%) 9 (5.1%) 0.82 4 (5.1%) 4 (4.0%) 2 (9.1%) 0.82
1-y Pancreas graft survival 93% 92% 94% 0.30 95% 95% 91% 0.68
1-y Patient survival 97% 97% 98% 0.24 99% 99% 96% 0.56
Simultaneous pancreas-kidney (n = 328)
1-y Pancreas graft survival 93% 93% 94% 0.91 93% 95% 89% 0.92
1-y Kidney graft survival 95% 95% 97% 0.38 95% 98% 100% 0.75
1-y Patient survival 97% 97% 98% 0.55 98% 98% 100%
a Calculated P value for donor cardiopulmonary arrest groups compared with the “no donor cardiopulmonary arrest” group.
4 Transplantation DIRECT ■ 2018 www.transplantationdirect.comcompleted in the fields of liver and intestine transplantation,
our results support the utilization of pancreas grafts from do-
nors with a history of PPCAwhen appropriately selectedwith
respect to other factors. Prolonged periods of asystole were as-
sociated with higher peak elevations in serum lipase in the do-
nor, but lower peak amylase elevations in the recipient. These
findings may support the hypothesis of a potential ischemic
preconditioning event which has been discussed previously in
the context of liver transplantation.
Clinical outcomes and survival rates were comparable
among grafts from all donor groups, including donors with
and without PPCA and among all donors with PPCA. In all
outcomes measured in this study, donor PPCAwas not statis-
tically associated with detrimental effects. Additionally,
among donors experiencing PPCA, an increased length of ar-
rest time was also not associated with worse outcomes,
though there was a trend toward worse long-term graftFIGURE 1. A, Ten-year Cox regression for pancreas graft survival c
preprocurement cardiac arrest. B, Ten-year Cox regression for pancreas
(n = 176), comparing groups by total arrest time (in minutes).C, Ten-year C
(n = 328), grouped by preprocurement cardiac arrest.survival for PPCA or 40 minutes or more that did not reach
statistical significance.
In the current setting of too few pancreas allografts avail-
able for transplant, PPCA donors represent an important re-
source to pursue in expanding the donor pool. Note that this
study is a retrospective analysis from a single center, so this
only reflects pancreas allografts that appeared normal and
were therefore transplanted despite the donor down time. It
is certainly possible, as suggested by the preprocurement pan-
creas allocation suitability score, which includes PPCA as a
variable, that there were additional allografts from donors
with PPCA that were edematous, firm, inflamed, or had other
features of pancreatitis and were therefore not transplanted.
Preprocurement cardiopulmonary arrest time may help pre-
dict the appearance of the pancreas at the time of graft pro-
curement, but if it appears normal, the data in this study
support proceeding with transplantation.omparing donor grafts with (n = 176) and without (n = 430) any
graft survival for all donor grafts with preprocurement cardiac arrest
ox regression for kidney graft survival amongSPK transplant patients
© 2018 Wolters Kluwer Schroering et al 5REFERENCES
1. LossM, Drewitz KP, Apfelbacher CJ, et al. Why offered pancreases are re-
fused in the allocation process—a descriptive study using routine data
from Eurotransplant. Transplantation. 2013;95:1134–1141.
2. Vinkers MT, Rahmel AO, Slot MC, et al. How to recognize a suitable pan-
creas donor: a Eurotransplant study of preprocurement factors. Trans-
plant Proc. 2008;40:1275–1278.
3. Neidlinger NA, Odorico JS, Sollinger HW, et al. Can ‘extreme’ pancreas do-
nors expand the donor pool?Curr Opin Organ Transplant. 2008;13:67–71.
4. Fridell JA, Rogers J, Stratta RJ. The pancreas allograft donor: current
status, controversies, and challenges for the future. Clin Transplant.
2010;24:433–449.
5. Matsumoto CS, Kaufman SS, Girlanda R, et al. Utilization of donors who
have suffered cardiopulmonary arrest and resuscitation in intestinal trans-
plantation. Transplantation. 2008;86:941–946.
6. Totsuka E, Fung JJ, Urakami A, et al. Influence of donor cardiopulmonary
arrest in human liver transplantation: possible role of ischemic precondi-
tioning. Hepatology. 2000;31:577–580.
7. Hoyer DP, Paul A, Saner F, et al. Safely expanding the donor pool: brain dead
donors with history of temporary cardiac arrest. Liver Int. 2015;35:
1756–1763.
8. Levesque E, Hoti E, Khalfallah M, et al. Impact of reversible cardiac arrest
in the brain-dead organ donor on the outcome of adult liver transplanta-
tion. Liver Transpl. 2011;17:1159–1166.
9. Ambros JT, Herrero-Fresneda I, BorauOG, et al. Ischemic preconditioning
in solid organ transplantation: from experimental to clinics. Transpl Int.
2007;20:219–229.10. Axelrod DA, Sung RS, Meyer KH, et al. Systematic evaluation of pancreas
allograft quality, outcomes and geographic variation in utilization. Am J
Transplant. 2010;10:837–845.
11. Fridell JA, Powelson JA, Kubal CA, et al. Retrieval of the pancreas allograft
for whole-organ transplantation. Clin Transplant. 2014;28:1313–1330.
12. Fridell JA, Mangus RS, Powelson JA. Histidine-tryptophan-ketoglutarate
for pancreas allograft preservation: the Indiana University experience.
Am J Transplant. 2010;10:1284–1289.
13. Fridell JA, Powelson JA, Sanders CE, et al. Preparation of the pancreas al-
lograft for transplantation. Clin Transplant. 2011;25:E103–E112.
14. Fridell JA, Mangus RS, Hollinger EF, et al. The case for pancreas after kid-
ney transplantation. Clin Transplant. 2009;23:447–453.
15. Fridell JA, Milgrom ML, Henson S, et al. Use of the end-to-end anasto-
motic circular stapler for creation of the duodenoenterostomy for enteric
drainage of the pancreas allograft. J Am Coll Surg. 2004;198:495.
16. Fridell JA, Shah A,MilgromML, et al. Ipsilateral placement of simultaneous
pancreas and kidney allografts. Transplantation. 2004;78:1074.
17. Fridell JA, Milgrom ML, Henson S, et al. Use of the end-to-end anasto-
motic circular stapler for creation of the duodenoenterostomy for enteric
drainage of the pancreas allograft [corrected]. J Am Coll Surg. 2004;
198:495–497.
18. Shah AP, Chen JM, Fridell JA. Incidence and outcomes of cytomegalovi-
rus in pancreas transplantation with steroid-free immunosuppression.Clin
Transplant. 2015;29:1221–1229.
19. Fridell JA, Agarwal A, Powelson JA, et al. Steroid withdrawal for pancreas
after kidney transplantation in recipients on maintenance prednisone
immunosuppression. Transplantation. 2006;82:389–392.
